Protocol summary
-
Study aim
-
To evaluate the safety and efficacy of resveratrol as an adjunctive treatment in hospitalized COVID-19 patients
-
Design
-
Randomized controlled clinical trial with parallel assignment
-
Settings and conduct
-
This study will be conducted at Razi Hospital, Ahvaz, Iran, from July to August 2020. Hospitalized patients with RT-PCR-confirmed COVID-19 will be assessed according to the inclusion and exclusion criteria and will then be randomly allocated to the intervention or control group
-
Participants/Inclusion and exclusion criteria
-
Participants: Adult hospitalized patients with RT-PCR-confirmed COVID-19 who require continuous oxygen therapy and have unilateral or bilateral pulmonary involvement.
Inclusion criteria: Age ≥18 years, RT-PCR-confirmed COVID-19, hospitalization, requirement for continuous oxygen therapy, SpO₂ <93%, and unilateral or bilateral pulmonary involvement.
Exclusion criteria: Renal failure, neurological disorders, and known allergy or hypersensitivity to resveratrol.
-
Intervention groups
-
Intervention group: Resveratrol 500 mg three times daily (TDS), in addition to standard COVID-19 care.
Control group: Patients will receive standard COVID-19 treatment together with a placebo capsule identical in appearance to the resveratrol capsule
-
Main outcome variables
-
Length of hospital stay, measured from hospital admission to discharge
General information
-
Reason for update
-
This update is being made to correct and complete the information registered in the IRCT and to align the study protocol details with the final study information. Since this clinical trial was conducted during the early stages of the COVID-19 pandemic and under the specific circumstances of that period, some study details were initially registered based on the information and conditions available at that time. Following completion of the study and finalization of the study information, the details regarding the intervention, control group, eligibility criteria, study outcomes, and other methodological characteristics are being reviewed and updated. This update is intended to improve the accuracy, transparency, and consistency of the registered information in relation to the study conducted.
-
Acronym
-
-
IRCT registration information
-
IRCT registration number:
IRCT20200112046089N1
Registration date:
2020-06-25, 1399/04/05
Registration timing:
registered_while_recruiting
Last update:
2026-10-12, 1405/07/20
Update count:
1
-
Registration date
-
2020-06-25, 1399/04/05
-
Registrant information
-
-
Recruitment status
-
Recruitment complete
-
Funding source
-
-
Expected recruitment start date
-
2020-06-14, 1399/03/25
-
Expected recruitment end date
-
2020-07-15, 1399/04/25
-
Actual recruitment start date
-
2020-06-14, 1399/03/25
-
Actual recruitment end date
-
2020-09-15, 1399/06/25
-
Trial completion date
-
empty
-
Scientific title
-
Evaluating the Safety and Efficacy of Resveratrol as an Adjunctive Treatment in Hospitalized COVID-19 Patients: A Randomized Controlled Trial
-
Public title
-
Resveratrol as an Adjunctive Treatment in Hospitalized COVID-19 Patients
-
Purpose
-
Treatment
-
Inclusion/Exclusion criteria
-
Inclusion criteria:
Age ≥18 years
RT-PCR-confirmed COVID-19
Hospitalization due to COVID-19
Requirement for continuous oxygen therapy
Arterial oxygen saturation (SpO₂) <93%
Unilateral or bilateral pulmonary involvement
Hospitalization within 48 hours of symptom onset
Exclusion criteria:
Renal failure
Neurological disorders
Known allergy or hypersensitivity to resveratrol
-
Age
-
From 18 years old
-
Gender
-
Both
-
Phase
-
N/A
-
Groups that have been masked
-
- Participant
- Outcome assessor
-
Sample size
-
Target sample size:
60
Actual sample size reached:
44
-
Randomization (investigator's opinion)
-
Randomized
-
Randomization description
-
Eligible participants will be randomly allocated to either the intervention or control group using block randomization with blocks of 6 participants. The randomization sequence will be generated using WinPepi software, version 11.0. Each participant will be assigned a unique code (Uni Code) to maintain allocation concealment. Following randomization, participants will be allocated to either the resveratrol intervention group or the control group.
-
Blinding (investigator's opinion)
-
Double blinded
-
Blinding description
-
Participants and outcome assessors were blinded to the group allocation. To maintain blinding of the participants, the control group received a placebo capsule identical in appearance to the resveratrol capsule.
-
Placebo
-
Used
-
Assignment
-
Parallel
-
Other design features
-
Ethics committees
1
-
Ethics committee
-
-
Approval date
-
2020-05-16, 1399/02/27
-
Ethics committee reference number
-
IR.AJUMS.REC.1399.175
Health conditions studied
1
-
Description of health condition studied
-
COVID19
-
ICD-10 code
-
U07.1
-
ICD-10 code description
-
COVID-19, virus identified
Primary outcomes
1
-
Description
-
Length of hospital stay
-
Timepoint
-
From hospital admission until hospital discharge
-
Method of measurement
-
The length of hospital stay will be calculated as the duration from hospital admission to hospital discharge
Secondary outcomes
1
-
Description
-
Requirement for ventilatory support
-
Timepoint
-
During hospitalization
-
Method of measurement
-
The requirement for ventilatory support will be assessed based on the patient's clinical condition during hospitalization
2
-
Description
-
In-hospital mortality
-
Timepoint
-
During hospitalization
-
Method of measurement
-
Mortality will be assessed by recording the patient's survival or death during hospitalization
3
-
Description
-
C-reactive protein (CRP) level
-
Timepoint
-
Before and after the intervention
-
Method of measurement
-
CRP will be measured using peripheral blood samples collected before and after the intervention
4
-
Description
-
White blood cell count (WBC)
-
Timepoint
-
Before and after the intervention
-
Method of measurement
-
WBC will be measured using peripheral blood samples collected before and after the intervention
5
-
Description
-
Neutrophil count
-
Timepoint
-
Before and after the intervention
-
Method of measurement
-
Neutrophil count will be measured using peripheral blood samples collected before and after the intervention.
6
-
Description
-
Lymphocyte count
-
Timepoint
-
Before and after the intervention
-
Method of measurement
-
Lymphocyte count will be measured using peripheral blood samples collected before and after the intervention
7
-
Description
-
Lactate dehydrogenase (LDH) level
-
Timepoint
-
Before and after the intervention
-
Method of measurement
-
LDH will be measured using peripheral blood samples collected before and after the intervention
8
-
Description
-
Serum creatinine level
-
Timepoint
-
Daily during the study
-
Method of measurement
-
Serum creatinine will be assessed using peripheral blood samples and monitored daily for safety assessment
9
-
Description
-
Alanine aminotransferase (ALT) level
-
Timepoint
-
Daily during the study
-
Method of measurement
-
ALT will be assessed as part of liver function tests (LFTs) and monitored daily for safety assessment
10
-
Description
-
PRIEST score
-
Timepoint
-
Before and after the intervention
-
Method of measurement
-
The PRIEST score will be assessed according to the study protocol
Intervention groups
1
-
Description
-
Resveratrol 500 mg three times daily (TDS) in addition to standard COVID-19 care.
-
Category
-
Treatment - Drugs
2
-
Description
-
Placebo capsule resembling resveratrol in appearance, in addition to standard care for COVID-19
-
Category
-
Placebo
1
-
Sponsor
-
-
Grant name
-
-
Grant code / Reference number
-
-
Is the source of funding the same sponsor organization/entity?
-
Yes
-
Title of funding source
-
Ahvaz University of Medical Sciences
-
Proportion provided by this source
-
100
-
Public or private sector
-
Public
-
Domestic or foreign origin
-
Domestic
-
Category of foreign source of funding
-
empty
-
Country of origin
-
-
Type of organization providing the funding
-
Academic
Sharing plan
-
Deidentified Individual Participant Data Set (IPD)
-
Undecided - It is not yet known if there will be a plan to make this available
-
Study Protocol
-
Undecided - It is not yet known if there will be a plan to make this available
-
Statistical Analysis Plan
-
Undecided - It is not yet known if there will be a plan to make this available
-
Informed Consent Form
-
Undecided - It is not yet known if there will be a plan to make this available
-
Clinical Study Report
-
Undecided - It is not yet known if there will be a plan to make this available
-
Analytic Code
-
Undecided - It is not yet known if there will be a plan to make this available
-
Data Dictionary
-
Undecided - It is not yet known if there will be a plan to make this available